Literature DB >> 1464414

The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study.

S Kudlacek1, G Schernthaner.   

Abstract

No conclusive data are available about the long-term effect of insulin treatment in type 2 diabetic patients failing to maximal doses of sulfonylureas and caloric restriction. In total 160 non-obese type 2 diabetic patients with secondary failure were substituted with insulin using a diabetic teaching and care program. From these 160 patients 40 died within the observation period of five years; 102 patients had a complete five year follow-up, whereas the remaining 18 patients did not come to regular follow-up visits. Metabolic control parameters improved significantly in the 102 patients with the complete five year follow-up. Postprandial plasma glucose (16.0 mM vs 10.9 mM; p < 0.0001) and HbA1c values (8.7% vs 7.1%, p < 0.0001) decreased significantly from the state before to five years after insulin substitution. In addition, plasma lipid levels could be significantly lowered under insulin therapy (cholesterol 6.2 +/- 1.5 mM vs 5.4 +/- 3.6 mM, p < 0.0002; triglycerides 2.8 +/- 1.6 mM vs 2.4 +/- 2.1 mM, p < 0.01). However, we observed a significant weight gain (mean: 10.6 kg) associated with insulin application during the five year follow-up. Thus, the body-mass-index decreased from 28.9 at onset of type 2 diabetes to 24.5 (p < 0.0001) at time of secondary failure and increased again to 28.5 (p < 0.0001) at five years after onset of insulin treatment. Furthermore, small increases of plasma creatinine from 88.4 microM to 115 microM, as well as systolic (19.3 kPa to 20.7 kPa) and diastolic (10.7 kPa to 11.3 kPa) blood pressures were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464414     DOI: 10.1055/s-2007-1003367

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  A new self-completion outcome measure for diabetes: is it responsive to change?

Authors:  P Whitty; N Steen; M Eccles; E McColl; J Hewison; K Meadows; Z Clapp; A Hutchinson
Journal:  Qual Life Res       Date:  1997-07       Impact factor: 4.147

2.  A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.

Authors:  Richard M Bergenstal; Julio Rosenstock; Richard F Arakaki; Melvin J Prince; Yongming Qu; Vikram P Sinha; Daniel C Howey; Scott J Jacober
Journal:  Diabetes Care       Date:  2012-10-09       Impact factor: 19.112

Review 3.  Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.

Authors:  M E Tushuizen; M Diamant; R J Heine
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

Review 4.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

5.  Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Authors:  Julio Rosenstock; Sylvia K Shenouda; Richard M Bergenstal; John B Buse; Leonard C Glass; Cory R Heilmann; Anita Y M Kwan; Leigh A MacConell; Byron James Hoogwerf
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.